RESEARCH ETHICS AND PATIENT CONSENT
The patient received personalized treatment as participant of the RESILIENT trial (CTRI/2018/02/011808), which was previously approved by the Institutional Ethics Committees of Datar Cancer Genetics as well as HCG Manavata Cancer Centre. All Study Participants provided written Informed Consent prior to enrolment and sample collection. Study participants also consented to publication of deidentified data and findings. The RESILIENT trial was conducted in accordance with existing Ethical and Regulatory considerations including the Declaration of Helsinki.